Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.34
USD
|
+0.75%
|
|
-1.47%
|
+8.06%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
751.7
|
404.7
|
395.4
|
106.1
|
233.6
|
280.6
|
-
|
-
|
Enterprise Value (EV)
1 |
679.8
|
136
|
343.2
|
106.1
|
233.6
|
280.6
|
280.6
|
280.6
|
P/E ratio
|
-2.68
x
|
-1.01
x
|
-1.33
x
|
-1.13
x
|
-4.43
x
|
-4.62
x
|
-4.67
x
|
9.24
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.24
x
|
1.37
x
|
1.85
x
|
0.36
x
|
1.2
x
|
1.49
x
|
1.71
x
|
1.18
x
|
EV / Revenue
|
2.24
x
|
1.37
x
|
1.85
x
|
0.36
x
|
1.2
x
|
1.49
x
|
1.71
x
|
1.18
x
|
EV / EBITDA
|
-2,646,500
x
|
-1,173,317
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-2,846,388
x
|
-3,655,739
x
|
-1,562,739
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.95
x
|
1.68
x
|
4.91
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
118,943
|
144,539
|
174,960
|
183,962
|
188,389
|
209,372
|
-
|
-
|
Reference price
2 |
6.320
|
2.800
|
2.260
|
0.5770
|
1.240
|
1.340
|
1.340
|
1.340
|
Announcement Date
|
3/10/20
|
2/25/21
|
3/1/22
|
3/9/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
335
|
295.3
|
213.6
|
292.6
|
194.6
|
188.5
|
164.4
|
237.4
|
EBITDA
|
-284
|
-344.9
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-286.3
|
-376.4
|
-265.3
|
-63.18
|
-46.08
|
-64.48
|
-109.5
|
-17.02
|
Operating Margin
|
-85.46%
|
-127.47%
|
-124.23%
|
-21.59%
|
-23.67%
|
-34.2%
|
-66.6%
|
-7.17%
|
Earnings before Tax (EBT)
1 |
-286.3
|
-383.5
|
-282.8
|
-92.56
|
-51.92
|
-72.19
|
-116.4
|
-23.68
|
Net income
1 |
-279.7
|
-383.5
|
-282.8
|
-92.56
|
-51.92
|
-70.4
|
-115.8
|
-23.68
|
Net margin
|
-83.48%
|
-129.85%
|
-132.43%
|
-31.63%
|
-26.68%
|
-37.34%
|
-70.45%
|
-9.98%
|
EPS
2 |
-2.360
|
-2.770
|
-1.700
|
-0.5100
|
-0.2800
|
-0.2900
|
-0.2867
|
0.1450
|
Free Cash Flow
|
-264.1
|
-110.7
|
-253
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-78.83%
|
-37.49%
|
-118.47%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
2/25/21
|
3/1/22
|
3/9/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
48.76
|
59.6
|
61.7
|
126.8
|
48.96
|
55.18
|
40.13
|
56.38
|
42.05
|
56.2
|
46.09
|
49.51
|
43.58
|
49.3
|
40.31
|
EBITDA
|
-
|
-
|
-58.08
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-54.89
|
-66.16
|
-58.49
|
48.43
|
-47.99
|
-5.129
|
-24.83
|
-9.09
|
-12.87
|
1.374
|
-13.6
|
-10.38
|
-19.22
|
-21.28
|
-30.4
|
Operating Margin
|
-112.57%
|
-110.99%
|
-94.8%
|
38.21%
|
-98.02%
|
-9.3%
|
-61.88%
|
-16.12%
|
-30.6%
|
2.45%
|
-29.51%
|
-20.95%
|
-44.12%
|
-43.15%
|
-75.41%
|
Earnings before Tax (EBT)
1 |
-59.54
|
-70.68
|
-62.42
|
29.28
|
-51.86
|
-7.552
|
-26.22
|
-11.17
|
-14.49
|
0.613
|
-20.36
|
-16.4
|
-21.32
|
-14.12
|
-
|
Net income
1 |
-59.54
|
-70.68
|
-62.42
|
29.28
|
-51.86
|
-7.552
|
-26.22
|
-11.17
|
-14.49
|
0.613
|
-14.98
|
-11.75
|
-20.81
|
-22.86
|
-31.9
|
Net margin
|
-122.13%
|
-118.58%
|
-101.17%
|
23.1%
|
-105.92%
|
-13.69%
|
-65.34%
|
-19.82%
|
-34.46%
|
1.09%
|
-32.5%
|
-23.73%
|
-47.75%
|
-46.36%
|
-79.14%
|
EPS
2 |
-0.3400
|
-0.4000
|
-0.3500
|
0.1500
|
-0.2800
|
-0.0400
|
-0.1400
|
-0.0600
|
-0.0800
|
-
|
-0.0767
|
-0.0567
|
-0.0833
|
-0.0733
|
-0.0450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/1/22
|
5/9/22
|
8/4/22
|
11/3/22
|
3/9/23
|
5/8/23
|
8/25/23
|
11/8/23
|
3/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
71.9
|
269
|
52.3
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-264
|
-111
|
-253
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-54.3%
|
-119%
|
-175%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-31.6%
|
-54.2%
|
-48.4%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
883.9
|
707.7
|
584.8
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
3.240
|
1.670
|
0.4600
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
6.66
|
0.32
|
0.06
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
1.99%
|
0.11%
|
0.03%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
2/25/21
|
3/1/22
|
3/9/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
1.34
USD Average target price
5
USD Spread / Average Target +273.13% Consensus |
1st Jan change
|
Capi.
|
---|
| +8.06% | 281M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|